Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by J. Bar
Microscopic mechanism of displacive excitation of coherent phonons in a bulk Rashba semiconductor
Changing the macroscopic properties of quantum materials by optically activating collective lattice excitations has recently become a major trend in solid state physics. One of the most commonly employed light-matter interaction routes is the displacive mechanism. However, the fundamental contribution to this process remains elusive, as the effects of free-carrier density modification and raised effective electronic temperature have not been disentangled yet.
Intrahepatic portosystemic shunt: salvage mechanism for oligohydramnios complicating fetal growth restriction
Supporting Information Filename Description uog29163-sup-0001-TableS1.docxWord 2007 document , 16.5 KB Table S1 Characteristics of 12 cases in which transient oligohydramnios and a congenital intrahepatic portosystemic shunt were diagnosed REFERENCES 1, , , et al. Congenital Portosystemic Shunts in Children: Associations, Complications, and Outcomes. Dig Dis Sci. 2020; 65: 1239-1251. 2, , , et al. Congenital portosystemic shunts: diagnosis and treatment. Abdom Radiol (NY). 2018; 43: 2023-2036. 3, , .
Evidence for cutaneous dysbiosis in dystrophic epidermolysis bullosa
ORIGINAL ARTICLE E. Sprecher Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Search for more papers by this author E.
Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer - Annals of Oncology
Highlights • Quavonlimab, a novel anti–CTLA-4 antibody, in combination with pembrolizumab was investigated in a first-in-human study. • The combination therapy was safe and tolerable and showed antitumor activity in patients with advanced NSCLC. • Data from this study led to a recommended phase II dose of 25 mg Q6W for quavonlimab when used with pembrolizumab.
Treatment of epidermolysis bullosa pruriginosa‐associated pruritus with dupilumab
RESEARCH LETTER L.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with J.
Contact J., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack